The "SWI5 Homologous Recombination Repair Protein" (SWI5 HRRP) is a theoretical protein associated with the cellular mechanism of homologous recombination repair (HRR), a critical process for maintaining genomic stability. Homologous recombination is a high-fidelity DNA repair pathway that is particularly active during the S and G2 phases of the cell cycle when sister chromatids are available as templates for repairing DNA double-strand breaks (DSBs).SWI5 HRRP is likely named after the SWI5 gene, which in yeast encodes a protein that plays a role in the regulation of the cell cycle and is involved in the repair of DSBs through homologous recombination. Drawing parallels from the yeast SWI5, the SWI5 HRRP in higher eukaryotes could be implicated in the recruitment of repair machinery to the sites of DSBs, ensuring that the HRR pathway is efficiently initiated.
The involvement of SWI5 HRRP in HRR suggests it may interact with key components of the repair process, such as the RAD51 recombinase, which catalyzes the strand invasion and exchange steps of HRR. SWI5 HRRP could function to enhance the formation of the RAD51 nucleoprotein filament, which is essential for searching for and pairing with the homologous DNA sequence on the sister chromatid.Furthermore, SWI5 HRRP might be involved in the resolution of Holliday junctions, the crossover structures formed during recombination, thereby facilitating the accurate completion of the repair process. It might also have a role in the regulation of the cell cycle checkpoints to ensure that cells do not proceed through mitosis with unresolved DNA damage, which could lead to chromosomal aberrations and genomic instability.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $206.00 $299.00 $485.00 | 10 | |
A PARP inhibitor, impairing DNA damage repair by blocking PARP1 and PARP2, affecting HR repair indirectly. | ||||||
Rucaparib | 283173-50-2 | sc-507419 | 5 mg | $150.00 | ||
Another PARP inhibitor, used for BRCA-mutated ovarian cancer by inhibiting DNA repair processes. | ||||||
Niraparib | 1038915-60-4 | sc-507492 | 10 mg | $150.00 | ||
Targets PARP enzymes, leading to increased DNA damage and cell death in cancer cells with HR deficiencies. | ||||||
Talazoparib | 1207456-01-6 | sc-507440 | 10 mg | $795.00 | ||
A potent PARP inhibitor, enhancing DNA damage in BRCA1/2-deficient cells by inhibiting DNA repair. | ||||||
Veliparib | 912444-00-9 | sc-394457A sc-394457 sc-394457B | 5 mg 10 mg 50 mg | $178.00 $270.00 $712.00 | 3 | |
Inhibits PARP1 and PARP2, disrupting DNA repair and potentiating chemotherapy and radiation therapy. | ||||||
NU 7441 | 503468-95-9 | sc-208107 | 5 mg | $350.00 | 10 | |
A DNA-PKcs inhibitor, leading to impaired non-homologous end joining (NHEJ) and affecting HR indirectly. | ||||||
AZD-0156 | 1821428-35-6 | sc-507529 | 10 mg | $280.00 | ||
Targets ATM kinase, impacting DNA damage response and potentially influencing HR repair processes. | ||||||